Overview
Filings disclosed on Friday show materially significant insider trading across a range of U.S.-listed companies. The activity spans purchases by directors and senior executives as well as major sales executed by investment vehicles and insiders following option exercises. The data below presents the material details disclosed, including transaction dates, share counts, dollar values, and accompanying market context where reported.
Top buys
Alpha Metallurgical Resources, Inc. (NASDAQ:AMR)
Director Kenneth S. Courtis acquired 15,000 shares of Alpha Metallurgical Resources common stock on May 12, 2026, in a series of direct purchases amounting to roughly $2,838,325. The disclosed weighted average prices for these transactions ranged from $183.05 to $192.14 per share. After completing these purchases, Mr. Courtis is shown as directly holding 975,394 shares of AMR common stock. The filing notes the stock is trading at $179.69 and that Alpha Metallurgical Resources has a market capitalization of $2.29 billion. The disclosure also references a Fair Value analysis indicating the company appears undervalued, per InvestingPro data.
KBR, INC. (NYSE:KBR)
Shad E. Evans, Executive Vice President and Chief Financial Officer, registered a direct purchase of 8,375 shares of KBR common stock on May 13, 2026, at a reported per-share price of $30.60, bringing the aggregate value of the purchase to $256,275. Following this transaction, Mr. Evans is recorded as directly holding 43,725.46 shares of KBR common stock. The filing supplies the basic transaction details without additional commentary from management.
Pulse Biosciences, Inc. (NASDAQ:PLSE)
Director and ten percent owner Robert W. Duggan increased his stake in Pulse Biosciences through purchases of 660,233 shares on May 11, 2026, for an aggregate consideration of $12,999,987. The shares were acquired at a price of $19.69 per share and were obtained through the company’s at-the-market equity offering program established under an Equity Distribution Agreement dated February 19, 2026, with TD Securities (USA) LLC. The disclosures state that these trades were executed during an open trading window and in compliance with applicable securities laws, at the market bid price or better. The company’s shares subsequently rose to $24.57, which equates to a gain of nearly 25% from the purchase price. The filing also highlights the stock’s recent returns, citing a year-to-date gain of 79% and a one-year return of 49%.
GeneDx Holdings Corp. (NASDAQ:WGS)
Director and ten percent owner Keith A. Meister, together with Corvex Management LP, another ten percent owner, purchased Class A Common Stock of GeneDx Holdings Corp. between May 13 and May 15, 2026, totaling $13,765,344 in consideration. The transactions occurred at prices ranging from $38.28 to $39.92 per share. At the time of disclosure, the stock was trading at $40.75, having moved significantly lower from its 52-week high of $170.87 and down about 68% over the prior six months, according to InvestingPro data. The filing further notes the company’s 52-week low of $32.21, underscoring the price range in which these insider purchases were made. Details related to Corvex’s purchases specify that on May 13 it acquired 94,074 shares at a weighted average price of $38.82 per share, with individual trades priced between $38.21 and $39.20. An additional 70,926 shares were later purchased at a weighted average of $39.45, with individual transaction prices between $39.21 and $39.80.
Westrock Coffee Co. (NASDAQ:WEST)
Director Joe T. Ford acquired a total of 31,500 shares of Westrock Coffee common stock across several transactions conducted on May 13 and May 14, 2026, for an approximate total of $266,630. Purchase prices ranged from $8.43 to $8.50 per share. The filing states the company’s shares are trading at $8.45 and have appreciated about 107% over the past six months. InvestingPro analysis cited in the filing indicates WEST appears overvalued relative to its Fair Value and that short-term technical indicators such as the Relative Strength Index point to overbought conditions. The disclosed transactions include a direct purchase of 8,000 shares at $8.43 per share on May 13, as well as indirect acquisitions that day of 3,500 shares at $8.44 and 5,000 shares at $8.43 through trusts for which Mr. Ford is trustee. On May 14, an additional 15,000 shares were indirectly acquired through one of those trusts at a weighted average price of $8.50 per share, with individual trade prices between $8.45 and $8.55. The filing notes Mr. Ford disclaims beneficial ownership of shares held by trusts where he lacks a pecuniary interest.
Top sells
DigitalOcean Holdings, Inc. (NASDAQ:DOCN)
Reporting entities associated with Access Industries - identified as AI Droplet Holdings LLC and AI Droplet Subsidiary LLC - sold a combined total of 3,300,000 shares of DigitalOcean common stock on May 13, 2026, at a sale price of $150.30 per share. The aggregate proceeds from these dispositions were approximately $496 million. Breakdown in the filing shows AI Droplet Holdings LLC sold 3,278,988 shares and AI Droplet Subsidiary LLC sold 21,012 shares. The filings say these sales were carried out as an unregistered block sale transaction pursuant to Rule 144. The filing situates this activity with the company trading near its 52-week high of $164.77 after a reported 398% gain over the prior year. InvestingPro analysis included in the disclosure characterizes the stock as appearing overvalued relative to Fair Value and notes technical indicators such as RSI point to overbought territory.
Venture Global, Inc. (VG)
Musser Fory, Senior Vice President of Development at Venture Global, sold 2,000,000 shares of Class A Common Stock on May 14, 2026. The sales were executed in multiple transactions at a reported weighted average price of $13.0863 per share, with individual trade prices spanning from $13.00 to $13.26. The total proceeds for these dispositions were approximately $26,172,600. The filing explains these sales followed a contemporaneous acquisition of the same number of shares through the exercise of stock options. The options were exercised at a price of $0.79 per share, resulting in an aggregate exercise cost of $1,580,000. The filing notes the options were fully vested and exercisable and have an expiration date of June 26, 2027. The disclosures are presented alongside market context that shows VG shares had risen about 14% over the past week and roughly 64% over the prior six months, and that the company’s market capitalization stands at $35.33 billion per InvestingPro data.
Venture Global also disclosed transactions by Keith D. Larson, General Counsel and Secretary, who sold approximately $15.06 million worth of Class A Common Stock over May 14 and May 15, 2026. These sales followed option exercises. The filing provides specific detail that on May 14 Mr. Larson exercised options to acquire 555,556 shares at an exercise price of $0.79 per share and immediately sold all 555,556 shares. The sales yielded a weighted average price of $13.0671 per share, with the range of individual sale prices between $12.80 and $13.26.
Sotera Health Co (NASDAQ:SHC)
Affiliated entities of private equity firm Warburg Pincus reported the sale of 19,102,952 shares of Sotera Health common stock on May 13, 2026, through an underwritten public secondary offering. The transactions generated approximately $289,753,575 in proceeds at an average price of $15.168 per share. The filing indicates these Warburg Pincus entities no longer hold any Sotera Health common stock following the offering. Separately, Chicago-based GTCR investment funds sold 12,735,301 shares of Sotera common stock as part of the same underwritten public secondary offering on May 13, 2026. That block was sold at $15.168 per share for aggregate proceeds of approximately $193,169,045, and the filing states GTCR entities likewise no longer hold any shares of Sotera common stock after the transactions. At the time of disclosure, the share price was trading at $15.27 and the company had a market capitalization of $4.42 billion. The filings additionally present valuation metrics, reporting a price-to-earnings ratio of 38.64 and a PEG ratio of 0.1, and InvestingPro analysis characterizes Sotera as appearing undervalued relative to near-term earnings growth.
What the filings collectively show
The documented purchases are concentrated among individual directors and senior executives who increased their holdings in companies across diverse sectors - mining, aerospace and defense contracting, medical devices, genetic testing and consumer-packaged goods. Purchases were carried out through direct buys and, in some cases, at-the-market offering mechanisms or via trusts. The sales include block dispositions by investment entities, option exercises followed by immediate sales by insiders, and an underwritten public secondary offering by private equity holders. The filings provide both micro-level detail on transaction mechanics and macro-level context on trading prices and recent returns.
Contextual considerations cited in the filings
- Several filings reference valuation context: Alpha Metallurgical Resources is cited as appearing undervalued by Fair Value analysis, while Westrock Coffee and DigitalOcean are characterized as appearing overvalued relative to Fair Value.
- Technical indicators and return metrics were supplied for certain names: Pulse Biosciences is reported to have strong year-to-date and one-year returns, Westrock has a notable six-month gain and a potentially overbought RSI, and DigitalOcean is trading near its 52-week high after a large one-year gain.
- Option mechanics and vesting schedules were disclosed for Venture Global insiders, including exercise prices, exercise dates, and option expiration dates.
- For Sotera Health, large secondary offerings resulted in Warburg Pincus and GTCR entities exiting their positions completely, and valuation ratios were provided alongside market capitalization.
Investor takeaway
Insider transactions are one data point among many. The filings compiled here show a mixture of convictions and liquidity events: directors and executives initiating or adding to positions in certain companies, and large holders or insiders monetizing stakes in others. Such activity can reflect a variety of motives that range from confidence in near-term company prospects to portfolio management or fulfillment of liquidity needs. The filings themselves, however, present concrete, dated transaction-level information that market participants can use alongside fundamental and technical analyses when assessing a company.
Disclosure
No additional commentary has been added beyond the details provided in the reported filings summarized above.